1. Home
  2. RYTM vs CUZ Comparison

RYTM vs CUZ Comparison

Compare RYTM & CUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • CUZ
  • Stock Information
  • Founded
  • RYTM 2008
  • CUZ 1958
  • Country
  • RYTM United States
  • CUZ United States
  • Employees
  • RYTM 283
  • CUZ N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • CUZ Real Estate Investment Trusts
  • Sector
  • RYTM Health Care
  • CUZ Real Estate
  • Exchange
  • RYTM Nasdaq
  • CUZ Nasdaq
  • Market Cap
  • RYTM 6.9B
  • CUZ 4.7B
  • IPO Year
  • RYTM 2017
  • CUZ N/A
  • Fundamental
  • Price
  • RYTM $102.12
  • CUZ $29.48
  • Analyst Decision
  • RYTM Strong Buy
  • CUZ Buy
  • Analyst Count
  • RYTM 13
  • CUZ 9
  • Target Price
  • RYTM $101.92
  • CUZ $32.22
  • AVG Volume (30 Days)
  • RYTM 550.8K
  • CUZ 1.4M
  • Earning Date
  • RYTM 11-04-2025
  • CUZ 10-23-2025
  • Dividend Yield
  • RYTM N/A
  • CUZ 4.35%
  • EPS Growth
  • RYTM N/A
  • CUZ N/A
  • EPS
  • RYTM N/A
  • CUZ 0.37
  • Revenue
  • RYTM $156,287,000.00
  • CUZ $917,942,000.00
  • Revenue This Year
  • RYTM $44.69
  • CUZ $13.63
  • Revenue Next Year
  • RYTM $63.53
  • CUZ $3.36
  • P/E Ratio
  • RYTM N/A
  • CUZ $79.19
  • Revenue Growth
  • RYTM 53.55
  • CUZ 11.98
  • 52 Week Low
  • RYTM $45.91
  • CUZ $24.07
  • 52 Week High
  • RYTM $106.52
  • CUZ $32.55
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 60.62
  • CUZ 63.95
  • Support Level
  • RYTM $101.45
  • CUZ $28.85
  • Resistance Level
  • RYTM $106.52
  • CUZ $29.49
  • Average True Range (ATR)
  • RYTM 3.12
  • CUZ 0.52
  • MACD
  • RYTM -0.43
  • CUZ 0.18
  • Stochastic Oscillator
  • RYTM 65.84
  • CUZ 90.95

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About CUZ Cousins Properties Incorporated

Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.

Share on Social Networks: